BioNTech co-founders Özlem Türeci (L) and Uğur Şahin (Horst Galuschka/picture-alliance/dpa/AP Images)

#AS­CO22: BioN­Tech says mR­NA vac­cine safe in 15 of 16 pa­tients with dead­ly pan­cre­at­ic can­cer

CHICA­GO — Pan­dem­ic vac­cine break­out BioN­Tech is back with more da­ta on its in­di­vid­u­al­ized mR­NA can­cer jab known as au­to­gene ce­vumer­an in the most com­mon form of pan­cre­at­ic can­cer.

While the Genen­tech-part­nered vac­cine is in two Phase II tri­als, BioN­Tech used this year’s AS­CO to present da­ta on a sin­gle-site Phase I study of the jab in pa­tients with a pan­cre­at­ic can­cer that leads to about 90% of pa­tients dy­ing with­in two years of their di­ag­no­sis.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.